meta-hydroxyephedrine

Small moleculeexperimentalImaging agent

Clinical trial activity

3 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2015 (NCT02669563)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
11-carbon

Oral

No

Parenteral

No

Topical

No

Also known as

  • 11c-hydroxyephedrine-meta
  • 11c-meta-hydroxyephedrine
  • 3-hydroxyephedrine
  • hcl(r-(r*,s*))-isomer of 3-hydroxyephedrine
  • meta-hydroxyephedrine
  • meta-hydroxyephedrine
  • meta-hydroxyephedrine
  • m-hydroxyephedrine
  • r-(r*,s*)-isomer of 3-hydroxyephedrine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03388788Early Phase 1 (Phase 1)May 1, 2018Oregon Health and Science University
NCT02962076N/ADec 1, 2016Biosense Webster, Inc., Mercy Health Research, Mercy Research, Washington University in St. Louis
NCT02669563Early Phase 1 (Phase 1)Dec 1, 2015University of Michigan
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Biosense Webster, Inc.For profit1012016
Mercy Health ResearchAcademic/Hospital1012016
Mercy ResearchAcademic/Hospital1112016
Oregon Health and Science UniversityAcademic/Hospital1112018
University of MichiganAcademic/Hospital1112015
Washington University in St. LouisAcademic/Hospital1012016
6 organizations
Page 1 / 1